Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Inclusion Criteria:

* Presence of at least one target liver or other intra-abdominal lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging: Target lesion must measure \>=1.0 cm in long axis diameter on CT or MRI
* The subject is able and willing to comply with study procedures and provide signed and dated informed consent.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Adequate organ function, including creatinine \< 1.5 x ULN or estimated creatinine clearance \>=500 mL/min (by the Cockcroft Gault equation) and total bilirubin \<3x upper limit of normal (ULN).

Part B only:

* No prior local therapy to target lesion.
* If patient agrees to optional biopsy:

  * Presence of at least one target lesion amenable to percutaneous tumor biopsy in the judgment of Interventional Radiology
  * No history of bleeding diathesis.
  * Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.
* Planned treatment with agent targeting PI3K/mTOR pathway (either standard of care or investigational agent)

Exclusion Criteria:

* Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
* Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
* Metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.
* Poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg. The addition of anti-hypertensives to control blood pressure is allowed.
* Congestive heart failure or New York Heart Association (NYHA) status ≥ 2.
* A history of clinically significant EKG abnormalities, including QT prolongation (QTcF \> 500 ms), a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.
* Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.